TapewireFind a company

person · Reporting owner

Ring Christine

Disclosed activity across 1 company

Tapewire entity
1157
SEC CIK
0001817199

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nurix Therapeutics, Inc.NRIX · Entity 1156Chief Legal OfficerOctober 02, 2026October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nurix Therapeutics, Inc.

Report date October 02, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,110 Ending reported balance After 2026-10-02 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12Direct111,251 Reported balance After 2026-10-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,762

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,762

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 01, 2024 Filed Jul 1, 2024 22:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,546

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
July 01, 2024 Filed Jul 1, 2024 22:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 801 $21.57 $17,277.33
Disclosure

SEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.31 and the highest price at which shares were sold was $22.05. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 01, 2024 Filed Jul 1, 2024 22:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 4,959 $20.68 $102,559.56
Disclosure

SEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,639

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.24 and the highest price at which shares were sold was $21.13. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 01, 2024 Filed Jul 1, 2024 22:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
June 13, 2024 Filed Jun 13, 2024 22:39 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,864 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,306

Underlying: Common Stock · 1,864 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
June 13, 2024 Filed Jun 13, 2024 22:39 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,864 $17.02 $31,721.18
Disclosure

SEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.07. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 13, 2024 Filed Jun 13, 2024 22:39 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,864 $1.86 $3,467.04
Disclosure

SEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 23:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,900 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,170

Underlying: Common Stock · 1,900 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 23:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,900 $17.01 $32,319.00
Disclosure

SEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 12, 2024 Filed Jun 12, 2024 23:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,900 $1.86 $3,534.00
Disclosure

SEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,738

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
June 05, 2024 Filed Jun 5, 2024 22:01 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,070

Underlying: Common Stock · 400 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
June 05, 2024 Filed Jun 5, 2024 22:01 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 400 $17.00 $6,801.00
Disclosure

SEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 05, 2024 Filed Jun 5, 2024 22:01 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $1.86 $744.00
Disclosure

SEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
June 03, 2024 Filed Jun 3, 2024 22:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,596 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,470

Underlying: Common Stock · 1,596 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
June 03, 2024 Filed Jun 3, 2024 22:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,596 $17.01 $27,152.91
Disclosure

SEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 03, 2024 Filed Jun 3, 2024 22:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,596 $1.86 $2,968.56
Disclosure

SEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,469

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,513 $12.04 $18,219.85
Disclosure

SEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,838

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.9050 and the highest price at which shares were sold was $12.2000. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 45,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000019 · wk-form4_1707999786.xml · derivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $8.72 $0.00
Disclosure

SEC source: 0001549595-24-000019 · wk-form4_1707999786.xml · derivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-02-12

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,393

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,760 $7.99 $14,062.75
Disclosure

SEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,427

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,232 $5.20 $6,403.20
Disclosure

SEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,263

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $5.04 and the highest price at which shares were sold was $5.28. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,317

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 27 shares of Common Stock acquired by the Reporting Person on August 15, 2023, pursuant to the Issuer's employee stock purchase plan.

Read SEC document
July 31, 2023 Filed Aug 1, 2023 20:27 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,420 $9.65 $13,709.67
Disclosure

SEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,544

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.61 and the highest price at which shares were sold was $9.82. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:27 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043979 · doc4.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:27 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043979 · doc4.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,241

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:27 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,964

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:27 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,964

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2023 Filed May 2, 2023 20:32 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 682 $9.88 $6,735.64
Disclosure

SEC source: 0001209191-23-026519 · doc4.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,040

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

F1 · balance_after: Includes 1,537 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:32 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026519 · doc4.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,165

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:32 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026519 · doc4.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,537 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:11 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 24,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009709 · doc4.xml · derivative · entry 2

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:11 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 88,900 $0.00 Strike: $10.83 $0.00
Disclosure

SEC source: 0001209191-23-009709 · doc4.xml · derivative · entry 1

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,900

Underlying: Common Stock · 88,900 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005906 · doc4.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,089

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 848 $11.78 $9,989.10
Disclosure

SEC source: 0001209191-23-005906 · doc4.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,261

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005906 · doc4.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2022 Filed Nov 1, 2022 23:34 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 699 $12.88 $9,003.47
Disclosure

SEC source: 0001209191-22-055143 · doc4.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,185

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.